Italfarmaco S.p.A. announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ...

Dr. Falk Pharma’s norucholic acid (NCA) drug has demonstrated potential in a Phase III trial for primary sclerosing ...

Treatment with givinostat has received fast track designation from the United States Food and Drug Administration for ...

Donald Trump has promised to create a pro-AI environment, but even tech companies are frustrated by federal cuts that hamper regulatory processes. Paul Webster reports.

The global cervical spacer systems market is experiencing strong growth and is projected to more than double over the next decade. Valued at USD 437.3 million in 2025, the market is anticipated to ...

The European Union's health regulator said on Wednesday it was reviewing French drugmaker Valneva's chikungunya vaccine after ...

Amtagvi has the potential to be approved in three new markets in 2025, including the United Kingdom, Canada, and all EU member states. Recently, the i CTC and Iovance's contract manufacturer ...

The FDA extended aficamten's review by three months for REMS safety program finalization, causing Cytokinetics' stock to drop ...

The FDA has granted Fast Track designation to Italfarmaco S.p.A.’s givinostat for the treatment of patients with polycythemia vera (PV).

The U.S. Food and Drug Administration (FDA) recently announced it plans to phase out animal testing in the development of monoclonal ...